title: Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: A multicentre pilot study of the French geriatric oncology group (GERICO).
abstract: BACKGROUND
  Elderly metastatic cancer patients typically have short life expectancy and frequently suboptimal treatment. Goals of therapy should include preservation of functional status as well as clinical response. For elderly patients, oral chemotherapy could be a valuable strategy, avoiding the constraints and risks of intravenous drugs.
  
  
  METHODS
  This study assessed effect of an all-oral combination of capecitabine and vinorelbine on functional status (measured by basic Activities of Daily Living [ADL]), toxicity, efficacy and compliance in patients ≥70 years with advanced breast, prostate or lung cancer.
  
  
  RESULTS
  Eighty patients were enrolled. After three cycles, 81.8% of patients had stabilised or improved ADL, and 8.6% and 42.9% had a response or stabilised disease. Compliance was excellent (68.8%). The most common grade 3-4 toxicities were haematological (17.9%) and gastrointestinal (7.7%).
  
  
  CONCLUSIONS
  In elderly cancer patients, an all-oral combination of capecitabine and vinorelbine maintains functional status, is well tolerated, and provides good disease control.
authors.affiliation: Pilot Unit of Research and Coordination in Geriatric Oncology, Department of Medicine, Institut PAOLI CALMETTES, 232 Bd Sainte Marguerite,13273 Marseille Cedex 9, France. rousseauf@marseille.fnclcc.fr
authors.forename: F
authors.initials: F
authors.lastname: Rousseau
authors.forename: F
authors.initials: F
authors.lastname: Retornaz
authors.forename: F
authors.initials: F
authors.lastname: Joly
authors.forename: B
authors.initials: B
authors.lastname: Esterni
authors.forename: S
authors.initials: S
authors.lastname: Abadie-Lacourtoisie
authors.forename: P
authors.initials: P
authors.lastname: Fargeot
authors.forename: E
authors.initials: E
authors.lastname: Luporsi
authors.forename: V
authors.initials: V
authors.lastname: Servent
authors.forename: B
authors.initials: B
authors.lastname: Laguerre
authors.forename: E
authors.initials: E
authors.lastname: Brain
authors.forename: J
authors.initials: J
authors.lastname: Geneve
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D016019:Survival Analysis; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D014747:Vinblastine; D000069287:Capecitabine; D000077235:Vinorelbine; D005472:Fluorouracil